Hormone Therapy News

SAN DIEGO — Men with hypogonadism do not appear to have any increased risk for venous thrombotic events with exogenous testosterone replacement therapy, according to research presented at The Endocrine Society annual meeting.

SAN DIEGO — Men who are referred for borderline testosterone levels have higher rates of depression and depressive symptoms compared with the general population, according to research presented at The Endocrine Society annual meeting.

SAN DIEGO — Estradiol increased glucose disposal rate among women who were in the last 6 years of menses, according to study findings presented here.

Unique processing strategies for working memory may be implemented by estrogen treatment in older postmenopausal women, according to study findings presented here.

SAN DIEGO — Menopausal hormone therapy does not appear to significantly alter the risk for all-cause mortality, or deaths related to cardiovascular disease or breast cancer, according to research presented at The Endocrine Society annual meeting.

SAN DIEGO — An estimated 26 to 33 million total prescriptions are filled annually for custom compounded menopausal hormone therapy, approaching the 36 million FDA-approved therapies prescribed, according to research presented at The Endocrine Society annual meeting.

The FDA has announced that manufacturers of prescription testosterone products must change their labeling to more clearly indicate approved uses and also include a warning about possible increased risk for MI and stroke.

A literature review recently published in the Journal of Clinical and Translational Endocrinology suggests that use of hormone therapy in transgender adults is relatively safe.

Female sexual dysfunction is multifaceted and complex, experts agree. Women seeking solutions are confronted with conflicting beliefs about the biological and psychological aspects of the disorder, and some contend that the FDA holds the pharmaceutical industry to a double standard when reviewing new therapies.

Sprout Pharmaceuticals has resubmitted a new drug application to the FDA for flibanserin, an investigational therapy to treat hypoactive sexual desire disorder in women during premenopause, according to a news release from the company.